What's new

Human medicines European public assessment report (EPAR): ellaOne, ulipristal acetate, Date of authorisation: 15/05/2009, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): ellaOne, ulipristal ac...

Human medicines European public assessment report (EPAR): Camcevi, leuprorelin, Date of authorisation: 24/05/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): Camcevi, leuprorelin, ...

Human medicines European public assessment report (EPAR): Tukysa, tucatinib, Date of authorisation: 11/02/2021, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): Tukysa, tucatinib, Dat...

Reflection paper on use of real-world data in non-inter...

Apr 3, 2025 0

Reflection paper on use of real-world data in non-interventional studies to gene...

Journey towards a roadmap for regulatory guidance on re...

Apr 3, 2025 0

Journey towards a roadmap for regulatory guidance on real-world evidence

Real-world evidence

Real-world evidence

Apr 3, 2025 0

Real-world evidence

Human medicines European public assessment report (EPAR): Litak, cladribine, Date of authorisation: 14/04/2004, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): Litak, cladribine, Dat...

Human medicines European public assessment report (EPAR): Yondelis, trabectedin, Date of authorisation: 17/09/2007, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): Yondelis, trabectedin,...

Human medicines European public assessment report (EPAR): Hetronifly, serplulimab, Date of authorisation: 03/02/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): Hetronifly, serplulima...

Human medicines European public assessment report (EPAR): Osenvelt, denosumab, Date of authorisation: 14/02/2025, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): Osenvelt, denosumab, D...

Human medicines European public assessment report (EPAR): Rystiggo, Rozanolixizumab, Date of authorisation: 05/01/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): Rystiggo, Rozanolixizu...

Human medicines European public assessment report (EPAR): Bylvay, odevixibat, Date of authorisation: 16/07/2021, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): Bylvay, odevixibat, Da...

Human medicines European public assessment report (EPAR): Copiktra, duvelisib, Date of authorisation: 19/05/2021, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): Copiktra, duvelisib, D...

Scientific and technical recommendations: Veterinary Medicines Regulation

Scientific and technical recommendations: Veterinary Me...

Apr 3, 2025 0

Scientific and technical recommendations: Veterinary Medicines Regulation

Human medicines European public assessment report (EPAR): Jardiance, empagliflozin, Date of authorisation: 22/05/2014, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 2, 2025 0

Human medicines European public assessment report (EPAR): Jardiance, empaglifloz...

Human medicines European public assessment report (EPAR): Extavia, interferon beta-1b, Date of authorisation: 20/05/2008, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 2, 2025 0

Human medicines European public assessment report (EPAR): Extavia, interferon be...

Human medicines European public assessment report (EPAR): Synjardy, empagliflozin,metformin, Date of authorisation: 27/05/2015, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 2, 2025 0

Human medicines European public assessment report (EPAR): Synjardy, empagliflozi...

EMEA-002565-PIP02-19-M01

EMEA-002565-PIP02-19-M01

Apr 2, 2025 0

EMEA-002565-PIP02-19-M01

EMEA-002656-PIP01-19-M01

EMEA-002656-PIP01-19-M01

Apr 2, 2025 0

EMEA-002656-PIP01-19-M01

Human medicines European public assessment report (EPAR): Pelmeg, pegfilgrastim, Date of authorisation: 20/11/2018, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 2, 2025 0

Human medicines European public assessment report (EPAR): Pelmeg, pegfilgrastim,...

Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, Online, from 18 March 2025, 09:30 (CET) to 18 March 2025, 13:00 (CET)

Meeting of the Medicine Shortages Single Point of Conta...

Apr 2, 2025 0

Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, ...

Joint HTAb-regulatory perspectives on understanding evi...

Apr 2, 2025 0

Joint HTAb-regulatory perspectives on understanding evidence challenges, managin...

Human medicines European public assessment report (EPAR): BroPair Spiromax, salmeterol,fluticasone propionate, Date of authorisation: 26/03/2021, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 2, 2025 0

Human medicines European public assessment report (EPAR): BroPair Spiromax, salm...

Biosimilar medicines: Overview

Biosimilar medicines: Overview

Apr 2, 2025 0

Biosimilar medicines: Overview

9
10
11
12
13

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.